Angelica dahurica is commonly referred to as ‘Baizhi’ in China and has been noted for its therapeutic significance. The major active ingredients of Angelica dahurica is coumarin, which is reported as a kind of potent inhibitor of cytochrome P450 enzymes (CYP450s). The aim of this study was to investigate the inhibition of CYP3A enzymes by total coumarin extract (TCE) obtained from dried root of Angelica dahurica by using in situ single pass intestinal perfusion (SPIP) and in situ liver perfusion in rats. When midazolam (MDZ) which is a substrate of CYP3A co-perfused with TCE (198 μg/mL) from Baizhi in duodenum and ileum segments, the Peff of MDZ has increased significantly compared with the MDZ single perfused group (p < 0.01) (n = 6). However, there was no significant effect on Peff of MDZ when it co-perfused with 66 μg/mL of TCE from Baizhi in both segments (p > 0.05) (n = 6). During in situ liver perfusion study, the results demonstrated that, 3 days oral administration of TCE obtained from Baizhi could significantly reduce the elimination rate of MDZ in the perfusate (p < 0.05) (n = 3). This study revealed that TCE from Baizhi had potent inhibition on CYP3A enzymes, and the inhibitory effect was related to dose. Therefore, when Angelica dahurica extract co-administrated with drugs which are the substrates of CYP3A, much more attention should be paid rather than that of other CYP450 enzymes. These findings may facilitate in predicting possible herb-drug interactions (HDIs) when Angelica dahurica is used in combination with other drugs, and decrease the incidence of the CYP450-mediated HDIs.
Yi, S.J., Joo-Youn, C., Soo, L.K., Kyu-Pyo, K., Jaewoo, K., Bo-Hyung, K., et al. (2009) Effects of Angelicae Tenuissima Radix, Angelica dahurica Radix and Scutellariae Radix Extracts on Cytochrome P450 Activities in Healthy Volunteers. Basic & Clinical Pharmacology & Toxicology, 105, 249-256. http://dx.doi.org/10.1111/j.1742-7843.2009.00423.x
Zhang, H., Gong, C.G., Lv, L., Xu , Y.J., Zhao, L., Zhu, Z.Y., Chai, Y.F. and Zhang, G.P. (2009) Rapid Separation and Identification of Furocoumarins in Angelica dahurica by High-Performance Liquid Chromatography with Diode-Array Detection, Time-of-Flight Mass Spectrometry and Quadrupole Ion Trap Mass Spectrometry. Rapid Communications in Mass Spectrometry RCM, 23, 2167-2175. http://dx.doi.org/10.1002/rcm.4123
Lee, H., Lee, J.K., Ha, H., Lee, M.Y., Seo, C.S. and Shin, H.K. (2012) Angelica dahurica Radix Inhibits Dust Mite Extract-Induced Atopic Dermatitis-Like Skin Lesions in NC/NGA Mice. Evidence-Based Complementary and Alternative Medicine, 2012, 614. http://dx.doi.org/10.1155/2012/743075
Ishihara, K., Kushida, H.M., Wakui, Y., Yanagisawa, T., Kamei, H., Ohmori, S., et al. (2000) Interaction of Drugs and Chinese Herbs: Pharmacokinetic Changes of Tolbutamide and Diazepam Caused by Extract of Angelica dahurica. Journal of Pharmacy & Pharmacology, 52, 1023-1029. http://dx.doi.org/10.1211/0022357001774750
Liska, D.J. (1998) The Detoxification Enzyme Systems. Alternative Medicine Review: A Journal of Clinical Therapeutic, 3, 187-198.
Venugopala, K.N., Rashmi, V. and Odhav, B. (2013) Review on Natural Coumarin Lead Compounds for Their Pharmacological Activity. Biomed Research International, 2013, 563-568.
Lian-Qing, G. and Yasushi, Y. (2004) Inhibition of Cytochrome P450 by Furanocoumarins in Grapefruit Juice and Herbal Medicines. Acta Pharmacologica Sinica, 2, 129-136.
Ho, P.C., Saville, D.J. and Wanwimolruk, S. (2001) Inhibition of Human CYP3A4 Activity by Grapefruit Flavonoids, Furanocoumarins and Related Compounds. Journal of Pharmacy & Pharmaceutical Sciences, 4, 217-227.
Ohnishi, A., Matsuo, H., Yamada, S., Takanaga, H., Morimoto, S., Shoyama, Y., Ohtani, H. and Sawada, Y. (2000) Effect of Furanocoumarin Derivatives in Grapefruit Juice on the Uptake of Vinblastine by Caco-2 Cells and on the Activity of Cytochrome P450 3A4. British Journal of Pharmacology, 130, 1369-1377. http://dx.doi.org/10.1038/sj.bjp.0703433
Yang, J., Hao, C., Yang, D., Shi, D., Song, X., Luan, X., et al. (2010) Pregnane X Receptor Is Required for Interleukin-6-Mediated Down-Regulation of Cytochrome P450 3A4 in Human Hepatocytes. Toxicology Letters, 197, 219-226. http://dx.doi.org/10.1016/j.toxlet.2010.06.003
Zhuang, X.M., Zhong, Y.H., Xiao, W.B., Li, H. and Lu, C. (2013) Identification and Characterization of Psoralen and Isopsoralen as Potent CYP1A2 Reversible and Time-Dependent Inhibitors in Human and Rat Preclinical Studies. Drug Metabolism & Disposition, 41, 1914-1922. http://dx.doi.org/10.1124/dmd.113.053199
Guengerich, F.P. (1998) Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism. Annual Review of Pharmacology & Toxicology, 39, 1-17. http://dx.doi.org/10.1146/annurev.pharmtox.39.1.1
Dahan, A. and Amidon, G.L. (2008) Segmental Dependent Transport of Low Permeability Compounds along the Small Intestine Due to P-Glycoprotein: The Role of Efflux Transport in the Oral Absorption of BCS Class III Drugs. Molecular Pharmaceutics, 6, 19-28. http://dx.doi.org/10.1021/mp800088f
Liang, S., Deng, F., Xing, H., Wen, H., Shi, X., Martey, O.N., et al. (2014) P-Glycoprotein- and Organic Anion-Transporting Polypeptide-Mediated Transport of Periplocin May Lead to Drug-Herb/Drug-Drug Interactions. Drug Design, Development & Therapy, 8, 475-483.
Chow, E.C.Y., Liu, L., Ship, N., Kluger, R.H. and Pang, K.S. (2008) Role of Haptoglobin on the Uptake of Native and β-Chain [Trimesoyl-(Lys82)β-(Lys82)β] Cross-Linked Human Hemoglobins in Isolated Perfused Rat Livers. Drug Metabolism & Disposition, 36, 937-945. http://dx.doi.org/10.1124/dmd.107.019174
Inoue, H., Tsuruta, A., Kudo, S., Ishii, T., Fukushima, Y., Iwano, H., Yokota, H. and Kato, S. (2005) Bisphenol a Glucuronidation and Excretion in Liver of Pregnant and Nonpregnant Female Rats. Drug Metabolism & Disposition, 33, 55-59. http://dx.doi.org/10.1124/dmd.104.001537
Fagerholm, U., Johansson, M. and Lennernäs, H. (1996) Comparison between Permeability Coefficients in Rat and Human Jejunum. Pharmaceutical Research, 13, 1336-1342. http://dx.doi.org/10.1023/A:1016065715308
Fasinu, P.S., Bouic, P.J. and Rosenkranz, B. (2012) An Overview of the Evidence and Mechanisms of Herb-Drug Interactions. Frontiers in Pharmacology, 3, 69. http://dx.doi.org/10.3389/fphar.2012.00069
Kabera, J.N., Semana, E., Mussa, A.R. and He, X. (2014) Plant Secondary Metabolites: Biosynthesis, Classification, Function and Pharmacological Properties. Journal of Pharmacy and Pharmacology, 2, 377-392.
Mitschke, D., Reichel, A., Fricker, G., et al. (2008) Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats. Drug Metabolism & Disposition, 36, 1039-1045. http://dx.doi.org/10.1124/dmd.107.019687
Takara, K., Ohnishi, N., Horibe, S., et al. (2003) Expression Profiles of Drug-Metabolizing Enzyme CYP3A and Drug Efflux Transporter Multidrug Resistance 1 Subfamily mRNAS in small Intestine. Drug Metabolism & Disposition, 31, 1235-1239. http://dx.doi.org/10.1124/dmd.31.10.1235
Gibbs, M.A., Thummel, K.E., Shen, D.D., et al. (1999) Inhibition of Cytochrome P-450 3A (CYP3A) in Human Intestinal and Liver Microsomes: Comparison of Ki Values and Impact of CYP3A5 Expression. Drug Metabolism & Disposition, 27, 180-187.
Jurica, J., Dostálek, M., Konecny, J., Glatz, Z., Hadasová, E. and Tomandl, J. (2007) HPLC Determination of Midazolam and Its Three Hydroxy Metabolites in Perfusion Medium and Plasma from Rats. Journal of Chromatography B, 852, 571-577. http://dx.doi.org/10.1016/j.jchromb.2007.02.034
Sherry, T.C. (2013) Endogenous Biomarkers of CYP3A Activity. University of Washington, Seattle.
Miroslav, D., Court, M.H., Bingfang, Y., et al. (2011) Significantly Reduced Cytochrome P450 3A4 Expression and Activity in Liver from Humans with Diabetes Mellitus. British Journal of Pharmacology, 163, 937-947. http://dx.doi.org/10.1111/j.1476-5381.2011.01270.x
Kaoru, K., Kikuko, U., Noriaki, S. and Kan, C. (2002) Substrate Specificity for Rat Cytochrome P450 (CYP) Isoforms: Screening with cDNA-Expressed Systems of the Rat. Biochemical Pharmacology, 63, 889-896. http://dx.doi.org/10.1016/S0006-2952(01)00843-7